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Abstract
Background: The objective of this study was to evaluate the efficacy of Nimesulide, a selective cyclooxygenase-2
(COX-2) inhibitor, on the growth of hypopharyngeal carcinoma cells (FaDu) in vitro, and investigate its potential
mechanism.
Methods: After FaDu cells were treated with graded concentrations of Nimesulide for divergent time, sensitivity of
cells to drug treatment was analyzed by MTT assay. Morphological changes of FaDu cells in the presence of
Nimesulide were observed by acridine orange cytochemistry staining. Proliferating cells were detected using the 5-
Bromo-2’-deoxy-uridine (BrdU) incorporation assay. Following cells were subjected to Nimesulide (500 μmol/l) for 6
h, 12 h and 24 h, the percentage of apoptosis was examined by flow cytometry. We detected COX-2 and Survivin
expression change by RT-PCR and Western blot, and analyzed the correlation of them with the growth of FaDu
cells. Additionally, we also analyzed Caspase-3, Bcl-2 and Bax expressions as markers to investigate the related
pathway of Nimesulide-indued apoptosis.
Results: Compared with the control group, the viabilities rates were decreased by Nimesulide in time- and dose-
dependent manners, typical morphological changes of apoptotic cells were observed in the Nimesulide-treatment
groups, Nimesulide could suppress the proliferation of FaDu cells significantly. The percentage of apoptosis in FaDu
cells were markedly increased after Nimesulide-treatment for 6 h, 12 h and 24 h. Nimesulide down-regulated the
Survivin and COX-2 expressions at mRNA and protein levels in FaDu cells. Additional analyses indicated that Bcl-2
expression was significantly decreased and the expressions of Caspase-3 as well as Bax were increased at both
mRNA and protein levels.
Conclusions: Based on the induction of apoptosis and suppression of proliferation, Nimesulide could inhibit the
growth of FaDu cells. Furthermore, the suppression of Survivin expression may play an important role in
Nimesulide-induced growth inhibition. Nimesulide could act as an effective therapeutic agent for hypopharyngeal
carcinoma therapy.
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Background
COX-2, a rate-limiting enzyme involved in conversion of
arachidonic acid to prostaglandins (PGs), has been
reported over-expression in a wide range of human malig-
nant tumors. More recently, it has been demonstrated that
COX-2 could contribute to carcinogenesis, prompt tumor
growth and progression, and closely associate with higher
risk of metastasis as well as poor survival [1-3]. Previous
studies have suggested that the inhibition of COX-2 has
anticancer effects in many kinds of cancers. Suppressing
COX-2 expression has effects on inhibition of carcinogen-
esis, and further may suppress the invasion of advanced
cancer [4,5]. Up to now, although many studies have
demonstrated that the selective COX-2 inhibitors were
useful agents on the cancer therapy, the exact mechanisms
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by which the COX-2 played anti-cancer effect remain
unclear. However, the administration of selective COX-2
inhibitors has come into research focus in the develop-
ment of new anti-cancer agents.
Survivin, a member of inhibitor of apoptosis protein
(IAP) family, is highly expressed in most human cancers
but not in normal tissues, and the up-regulation of Sur-
vivin expression generally means predictive of tumor
progression and poor prognosis. Its function in mitosis
is to preserve the mitotic apparatus and to allow normal
mitotic progression. Survivin is involved in the process
of apoptosis and its anti-apoptotic function is executed
via preventing Caspases activation [6,7]. A report from
Mehar et al. showed that COX-2 over-expression
increased levels of Survivin [8].
Hypopharyngeal carcinoma is common malignancy in
the head and neck region. Recently studies have demon-
strated that COX-2 over-expression was detected in
hypopharyngeal carcinomas [9,10]. However, there was
no data available regarding the anticancer effects of selec-
tive COX-2 inhibitors on hypopharyngeal carcinomas. In
present study, we firstly treated hypopharyngeal carci-
noma cell line with Nimesulide, a selective COX-2 inhibi-
tor, and evaluated its effects on the growth of FaDu cells.
Furthermore, we also detected the expression of Survivin
to investigate its role in Nimesulide-induced growth
inhibition.
Methods
Cell culture and drug treatment
FaDu cells was purchased from Shanghai Biosis Biotech-
nology Co.Ltd.. FaDu (approximately 15 × 104 cells/ml)
was seeded in culture flasks and incubated in DMEM
supplemented with 10% FBS at 37°C in the presence of
5% CO2 in a humidified incubator. Nimesulide were pur-
chased from Sigma. Concentrated drug stocks were
diluted in DMEM before administration to cells. Subse-
quently, Nimesulide were added to the medium (each at
final concentration of 500 μ mol/l), and according to the
result of our pre-experiment, the effect of necrosis is
higher than apoptosis, so FaDu cells were harvested after
6 h, 12 h of incubation, only the cells in flow cytometry
were incubated for 24 h.
MTT assay
MTT was performed to evaluate sensitivity of FaDu cells
to Nimesulide treatment. Briefly, FaDu cells were respec-
tively plated in a 96-well plate and further incubated for
24 h. Then, the medium was removed and cells were
exposed to fresh medium containing various combina-
tions of Nimesulide (10 μM to1000 μM) for 12 h, 24 h,
and 48 h. 20 μl MTT (5 g/l) was added to each well and
cultured for additional 4 h. Subsequently, the supernatant
was removed, 100 μl DMSO was added into each well
and shaken for another 20 min until the crystals were
dissolved. The absorption (A) was measured at 570 nm.
Controls consisted of untreated cells. Three independent
experiments were performed for each group.
Morphological observation
Morphological changes of FaDu cells in response to
Nimesulide treatment were evaluated by staining cells
with acridine orange. Briefly, after 24 h of incubation, the
medium was removed and refilled with new serum-free
medium containing Nimesulide (500 μ mol/l) for 6 h and
12 h incubation. Then the cells were stained by 0.01%
acridine orange for 5 min, the morphological changes
were examined by fluorescence microscope. Cells with
typical features of nuclear fragmentation and/or marked
condensation of chromatin with reduced nuclear size
were interpreted as apoptotic cells.
BrdU assay
The effect of Nimesulide on proliferation of FaDu cells
was detected by the BrdU incorporation assay. 15 × 104
cells/ml FaDu cells was seeded onto a cover glass in 24-
well plates. FaDu cells were treated with or without
Nimesulide (500 μmol/l) for 12 h, respectively. As
described in manufacturer’s manual (Roche Applied
Science), BrdU labeling medium was added to the cells
for 4 h in 37°C incubator. After washing the cells with
phosphate buffered solution (PBS) three times, cells was
incubated with anti-BrdU antibody in incubation buffer
overnight at 4°C, followed by incubation with anti-mouse
antibody for 30 min at 37°C. 4’, 6-diamidino-2-phenylin-
dole dihydrochloride (DAPI, Sigma-Aldrich) (2 μg/ml)
was used as nuclear staining for counterstaining. Images
were captured with a fluorescence microscope, and the
percentage of BrdU-labeled cells was calculated.
Flow cytometry analysis
Cell apoptotic progression was assessed by flow cytome-
try using Annexin V-FITC and propidium iodide (PI).
Cells were harvested by trypsinized, washed with phos-
phate-buffered saline (PBS). After washing, cells (1 × 106/
ml) were resuspended in Binding Buffer (200 μl) contain-
ing Annexin V-FITC (5 μl, 20 μg/ml) and PI (10 μl,
20 μg/ml) for at least 15 min at room temperature, and
then added Binding Buffer (300 μl) before analysis with a
SystemII(ver3.0) (Beckmand).
RNA extraction and RT-PCR
RNA was extracted using TRIzol (Invitrogen) from cul-
tured cells after being incubated with Nimesulide
(500 μmol/l) for 6 h and 12 h respectively. RNA was also
extracted from control group. The RT-PCR was performed
following the instruction of TaKaRa TaqTM to determine
the expession of Caspase-3, Bcl-2, Bax, Survivin and
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COX-2. b-actin was used as standard. The primers for the









COX-2: 5’ CAGGGTTGCTGGTGGTAGGA 3’;
5’ GAACACTGAATGAAGTAAAGGGACA 3’;
b-actin: F: 5’ GTGGGGCGCCCCAGGCACCA 3’;
R: 5’ GTGGGGCGCCCCAGGCACCA 3’
PCR products were electrophoresed on a 1% agarose
gel. The gel was then visualized and photographed
under UV light. The mRNA expressions were deter-
mined by comparing with b-actin. All experiments were
done in triplicate.
Protein extraction and western blot analysis
After protein extraction and determining the protein
concentration of the supernatant by Bradford method,
protein was separated by electrophoresis in 12.5%
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) gels according to their molecular
weight. After incubation with primary antibodies (Rabbit
anti-Human COX-2, 1:300; Survivin, 1:1000; Caspase-3,
Bcl-2 and Bax, 1:200; Mouse anti-human b-actin,
1:2000), and then, incubated with peroxidase-linked sec-
ondary antibody. Reactive bands were detected using
ECL chemiluminescence reagent (Amersham Bios-
ciences). The b-actin, COX-2, Survivin, Caspase-3, Bcl-2
and Bax bands were visualized at apparent molecular
weights of 43 kDa, 72 kDa, 16 kDa, 32 kDa, 26 kDa and
23 kDa, respectively. Relative OD value ratio was calcu-
lated with NIH software Image J by comparing to b-
actin from triplicate experiments.
Statistical analysis
Correlation analysis between expressions of target genes
in clinical tumor samples was done using the Student’s t
test. For statistical evaluation of cell culture experi-
ments, mean values and SD of the triplicate experiments
were calculated. Gene expression levels under treatment
with Nimesulide were compared with the respective
expression levels without drug treatment using Anova
test. SPSS 13. 0 statistical software (SPSS Inc) was used.
P values smaller 0.05 were considered as statistically
significant.
Results
Nimesuide suppressed the viability of FaDu cells
As shown in Figure 1, the relative viability of cells was sup-
pressed after incubation with Nimesulide. Taken control
as 100%, the relative viabilities of FaDu cells exposure to
Nimesulide at 10 μmol/l, 50 μmol/l, 100 μmol/l,
500 μmol/l, 1000 μmol/l for 24 h were (89.90 ± 7.83)%,
(78.80 ± 6.69)%, (70.57 ± 8.52)%, (60.10 ± 7.26)% and
(26.12 ± 11.7)%, respectively (P < 0.05). Taken the viability
of FaDu cells exposure to Nimesulide (500 μmol/l) at 0 h
as 100%, the relative viabilities of FaDu cells at 12 h, 24 h
and 48 h were (70.6 ± 8.81)%, (60.10 ± 7.26)% and (42.2 ±
5.59)% (P < 0.05).
Effects of nimesulide on morphological changes in FaDu
cells
Morphological changes of FaDu cells were examined by
inverted phase contrast microscope and acridine orange
cytochemistry staining at 6 h or 12 h after treated with
Nimesulide (500 μmol/l). As shown in Figure 2, compared
to control, the number of cells was significantly decresed
after Nimesulide treatment. The cells without Nimesulide
treatment showed polygonal shape, but, the cells treated
with Nimesulide for 12 h became rounded and had cyto-
plasmic contraction and chromatin condensation. Apopto-
tic bodies, as the main morphological characteristic of
Figure 1 Effects of Nimesulide on viability of FaDu cells. The
anti-proliferating effects of Nimesulide were evaluated by MTT
assay. Cells were treated with 0-1000 μM Nimesulide and the
percentage of growth inhibition was determined after 12 ~ 48 h of
treatment. FaDu cells had significant time- and dose-dependent
growth inhibition due to Nimesulide.
Jia-Jun et al. Head & Neck Oncology 2012, 4:7
http://www.headandneckoncology.org/content/4/1/7
Page 3 of 8
apoptosis, were detected obviously in cells treated with
Nimesulide.
BrdU assay on proliferating of FaDu cells
The number of the BrdU positive cells detected in control
group was more than that of Nimesulide treated group
(Figure 3) (P < 0.05). Compared to control, the percentage
of BrdU positive cells was significantly decreased to 30%
in cells with Nimesulide (500 μmol/l, 12 h). These results
were consistent with previous data showing that Nimesu-
lide helps to decrease the viability of FaDu cells.
Flow cytometry (FCM) analysis
Flow cytometric analysis (Figure 4) showed that the
apoptotic rates at 6 h, 12 h, or 24 h after the administra-
tion of Nimesulide (500 μmol/l) were (32.4 ± 6.1)% and
(45.87 ± 3.19)%, respectively, whereas, the control was
(4.17 ± 4.20)% (P < 0.05). After cells were incubated for
24 h, the effect of necrosis is higher than apoptosis; the
apoptotic rate was (44.57 ± 4.10)%.
The expression of survivin and COX-2 in FaDu cells after
nimesulide treatment
As shown in Figure 5, compared with control, the
mRNA and protein levels of both Survivin and COX-2
were all suppressed after treatment with Nimesulide for
6 h and 12 h. Concretely, taken control as 100%, after
FaDu were treated with Nimesulide for 6 h and 12 h,
protein expression of COX-2 was (51.8 ± 6.8)% and
(34.9 ± 2.4)%, respectively (P < 0.05), and that of Survi-
vin was (59.4 ± 6.9)% and (51.9 ± 5.6)% (P < 0.05).
The alteration of apoptosis related factors after
nimesulide treatment
Nimesulide induced the expressions of Caspase-3 and
Bax while Bcl-2 expression was down-regulated at both
mRNA and protein levels (Figure 6). Taken the proteins
expression control as 100%, Bcl-2 protein expression in
the cells treated with Nimesulide for 6 h and 12 h were
(55.1 ± 10.3)% and (32.1 ± 8.8)%, respectively (P < 0.05).
The expression of Bax protein were increased to 1.56 ±
0.38 and 2.8 ± 0.35-folds (P < 0.05). The protein expres-
sion of Caspase-3 increased about 1.75 ± 0.44 and 2.41
± 0.50-folds in the cells treated with Nimesulide for 6 h
and 12 h, respectively (P < 0.05).
Discussion
COX-2 is considered as an important potential regulator
of cancer growth and progression. There are currently
many lines of evidence from the literature that supports
the use of COX-2 inhibitors for cancer chemoprevention
in a variety of cancers [11]. However, relatively little
research has investigated the anti-cancer effects of var-
ious COX-2 inhibitors on hypopharyngeal carcinoma. In
Figure 2 Morphological changes of FaDu cells before and after Nimesulide-treatment (500 μmol/l, 24 h). Cells were stained with acridine
orange and detected by fluorescence microscopy (×200). A: The number of survival cells in Nimesulide treated group was much fewer than that
of control. B: Morphological changes and apoptotic bodies were detected obviously in Nimesulide group.
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Figure 3 Inhibition of cell proliferation was detected by BrdU incorporation assay after treatment with Nimesulide (500 μmol/l). A:
control group; B: treated with Nimesulide (500 μmol/l). a/d: The BrdU stained cells by immunofluorescence was detected by fluorescence
microscopy (×200); b/e: nuclear stained by DAPI was detected by fluorescence microscopy (×200), c/f: Direct detected by reserved microscopy
(×200).
Figure 4 Apoptotic rates of FaDu cells treated with Nimesulide were detected using FCM. The percentage of apoptosis cells was markedly
increased in the present of Nimesulide. × -axis represents the density of propidium iodide (PI), Y- axis represents the density of Annexin V-FITC.
A: control; B: 6 h, C: 12 h; D: 24 h.
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this study, the viability of FaDu cells was suppressed by
Nimesulide in time- and dose- dependent manners as
evidenced by MTT assay, which was similar with the
previous report that Nimesulide had an inhibitory effect
of human ovarian SKOV-3 tumors [12]. This result
could partly suggest that Nimesulide can reduce the
growth of FaDu cells. We hypothesized this result may
be based on two reasons. Firstly, the morphological test
showed that FaDu cells, in response to Nimesulide,
became rounded and had cytoplasmic contraction and
chromatin condensation, which represents the typical
morphological characteristics of apoptosis, and the Flow
cytometry analysis demonstrated that the percentage of
apoptosis were increased. Moreover, the BrdU positive
cells detected in the control group were more than those
in the treatment group. This indicated that Nimesulide
Figure 5 Alterations of Survivin and COX-2 expressions in FaDu cells. A: RT-PCR analysis. B: Western blot detection. The optical densities
(OD) value of mRNA (C) and proteins (D) in each lane using NIH software Image J system were demonstrated in different times treated with
Nimesulide. Each data point in the figure represents the mean ± SEM of three separate experiments.
Figure 6 The mRNA and protein levels of Bax, Bcl-2 and Caspase-3 in FaDu cells. A: RT-PCR analysis. B: Western blot measurement. The
optical densities (OD) value of mRNA (C) and proteins (D) in each lane using NIH software Image J system were demonstrated in different times
treated with Nimesulide. Each data point in the figure represents the mean ± SEM of three separate experiments.
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was able to inhibit the proliferation of FaDu cells. Over-
all, our findings suggested that Nimesulide exerts its anti-
tumor effect via anti-proliferation and apoptotic-inducing
pathway.
Previous studies have demonstrated that down-regula-
tion of COX-2 via siRNA treatment inhibited cell prolif-
eration and induced apoptosis in human esophageal
cancer cells [4]. As well known, the main role of selec-
tive COX-2 inhibitors is COX-2 activity suppress. The
relationship between selective COX-2 inhibitor and
COX-2 expression is controversial [13,14]. These con-
tradictory results may be due to the different experi-
ments systems (e.g. different drugs, dose and action
time or different cell lines). To further understand the
possible mechanism whereby Nimesulide-induced
growth inhibition, we detected COX-2 expression in
FaDu cells treated with Nimesulide. Similarly with pre-
vious reports, in the present study, we demonstrated a
more significant reduction of COX-2 expression levels
following the administration of Nimesulide in FaDu
cells. Our data also supported the current concept that
down-regulation of COX-2 may be involved in the regu-
lation of Nimesulide-reduced growth.
As a regulator of apoptosis, Survivin play a very domi-
nant effect in the anti-apoptotic process, and the over
expression of Survivin induced unlimited proliferation of
cancer cells. siRNA targeting Survivin inhibits growth
and induces apoptosis in human renal clear cell carci-
noma 786-O cells [15]. Previous studies have demon-
strated that selective COX-2 inhibitors could induce
apoptosis of cancer cells by inhibition of Survivin
expression [16,17]. In present study, we found that Sur-
vivin expression both at the mRNA and protein levels
were significantly reduced in the presence of Nimesulide
in FaDu cells, as demonstrated by RT-PCR and Western
blot analysis. The potent down-regulation of Survivin is
reminiscent of the association between Survivin and the
growth which was suppressed by Nimesulide.
To understand the potential mechanisms of Survivin-
related in the process of Nimesulide-induced growth
inhibition, we detected the downstream factors of it. In
the present report, considering the well-known function
of Survivin as an inhibitor of Caspases family, and Survi-
vin knock down-induced apoptosis seemed to be Bcl-2
and Bax-dependent [18,19]. We detected the expression
of Caspase-3, Bcl-2 and Bax in FaDu cells treated with
Nimesulide. Our results demonstrated that Caspase-3
and Bax expression were potently up-regulated, and the
expression of Bcl-2 was suppressed. All these results
suggested that Survivin may play an important role in
the Nimesulide-induced apoptosis.
In conclusion, Nimesulide could suppress the growth
of hypopharyngeal carcinoma cells via anti-proliferation
and apoptotic-inducing pathway in vitro, and the
expression of Survivin may play an important role in the
process. Our findings pave a way to selectively target
COX-2 to inhibit the growth of hypopharyngeal carci-
noma cells, and eventually for the treatment of hypo-
pharyngeal carcinoma in the future.
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